PDCD1 and neoplasm: Given the link between this cell population and immune suppression or therapy resistance, quantifying TIGIT+ Tex cell frequencies—possibly through minimally invasive methods such as peripheral blood sampling or tumor-draining lymph node biopsies—may help predict patient responsiveness to PD−1/TIGIT dual blockade or other immunotherapeutic combinations.